CELL-MEDICA
Cell Medica, a leading T cell therapeutics company, today announced the opening of its European commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology park of Campus Berlin-Buch (Germany). This state-of-the-art facility for the GMP production of cell and gene therapies includes approximately 350 m2 clean room space.
Initial manufacturing will focus on Cytovir™ CMV – an innovative treatment which uses the immune cells of a healthy donor to restore viral immunity against Cytomegalovirus infections in patients who are immunocompromized following allogeneic hematopoietic stem cell (bone marrow) transplant. The commercial launch of this product is planned in early 2014 and will confirm Cell Medica’s position as one of the leaders in the development and market delivery of T cell therapeutics – a new paradigm for the treatment of cancer and infections.
Dr. Rainer Knaus, Managing Director of Cell Medica GmbH and Head of the Company’s global manufacturing operations, commented: “This facility has been designed and equipped to provide high quality GMP compliant production of patient-specific cell and gene therapies for distribution across Europe. We are also very fortunate to have attracted highly educated and well-trained personnel who are keen to help shape this new era of cell-based therapeutics”, says Dr. Knaus. “These manufacturing specialists are preparing the facility for the supply of Cytovir CMV in early 2014.”
The facility in Berlin-Buch will also be important for Cell Medica’s planned CITADEL study for the investigation of Cell Medica’s T cell therapy for the treatment of EBV-associated lymphomas. The provision of investigational medicinal products for European study centers will be undertaken following the required regulatory approvals.
The financing of Cell Medica’s investment in the Berlin-Buch facility is supported in part by the Investitionsbank Berlin (IBB), the business development and promotional bank of the Federal Land of Berlin.
Notes to Editors
About Cell Medica
Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cancers related to oncogenic viruses. The Company’s lead cell product, Cytovir™ CMV, for the treatment and prevention of cytomegalovirus (CMV) infections in patients following allogeneic bone marrow transplant, is available in the UK and is under development in other territories. Cytovir™ ADV is being developed for the treatment of adenovirus infections in pediatric patients following bone marrow transplantation. Cell Medica is also working with the Center for Cell and Gene Therapy, Baylor College of Medicine, to develop a cancer cellular therapeutic for the treatment of malignancies associated with the oncogenic Epstein Barr Virus.
About T cell immunotherapy
T cell immunotherapy involves harnessing the power and precision of the human immune system to treat disease. Extensive academic research in the field of clinical immunology has provided early evidence that T cells may be used for the treatment of viral infections. Certain cancers are also associated with infection by viruses such as the Epstein-Barr Virus (EBV). Ongoing clinical research at UCL, Baylor College of Medicine and other institutions is exploring how T cell immunotherapy may be used to eliminate malignant cells which express viral antigens.
About Cytovir CMV
Cytovir™ CMV is available on clinician's request (UK only). It is comprised of naturally occurring CMV-specific cytotoxic T lymphocyte cells (T cells) that are directly selected from a seropositive donor. Cytovir CMV is under development by Cell Medica as a novel treatment for cytomegalovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplantation by means of virus-specific immune reconstitution.
In Germany, the competent authority has confirmed that Cytovir CMV can be placed on the market under a manufacturing license.
About cancer cellular therapeutics in development
Cell Medica is developing a formulation of autologous cytotoxic T cell lymphocytes expanded to target EBV tumor-associated antigens. This product is under early phase clinical development as a specific cancer cellular therapeutic for a subset of EBV-associated advanced relapsed, refractory lymphoma.
About IBB
Investitionsbank Berlin (IBB) is the business development and promotional bank of the Federal Land of Berlin. With a wide product spectrum it is active in the areas of business and property promotion. IBB supports small and medium-sized enterprises in Berlin with subsidies, loan products and equity stakes developing targeted solutions for its clients. In doing so it works in close cooperation with all local commercial banks.
Contact:
For more information, please contact:
Gregg Sando, CEO,
Cell
Medica Limited
+44 (0)20 7554 4070
www.cellmedica.co.uk
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum